Claims
- 1. A compound selected from the group consisting of:
- 3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H- thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 2-(2-Ethoxyethyl-)-4-ethylamino-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 2-(2-Ethoxy)ethyl-3,4-dihydro-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 4-Ethylamino-3,4-dihydro-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 3,4-Dihydro-2-[2-(methoxyethoxy)ethyl]-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-syulfonamide 1,1-dioxide; Ethylamino-3,4-dihydro-2-[2-(methoxyethoxy)ethyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide;
- 4-Ethylamino-3,4-dihydro-2-[3-(methoxyethoxy)propyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; and
- 3,4-Dihydro-2-[3-(methoxyethoxy)propyl]-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide.
- 2. The compound of claim 10 which is
- 3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide.
- 3. The Compound of claim 1 which is 4-Ethylamino-3,4-dihydro-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide -1,1-dioxide.
- 4. R-(+)-4-Ethylamino-3,4-dihydro-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide.
- 5. R-(+)-3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide.
- 6. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.
- 7. The formulation of claim 6 wherein the compound concentration is between about 0.1 and 10% by weight.
- 8. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 4 in a pharmaceutically acceptable carrier.
- 9. The formulation of claim 8 wherein the compound concentration is between about 0.1 and 10% by weight.
- 10. The formulation of claim 9 wherein the concentration is between about 0.25 wt % and 5.0 wt %.
- 11. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the Compound of claim 5 in a pharmaceutically acceptable carrier.
- 12. The formulation of claim 11 wherein the compound concentration is between about 0.1 and 10% by weight.
- 13. The formulation of claim 12 wherein the concentration is between about 0.25 wt % and 5.0 wt %.
- 14. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 1.
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 618,765, filed Nov. 27, 1990, now U.S. Pat. No. 5,153,192 which is a continuation-in-part of U.S. patent application Ser. No. 506,780, filed Apr. 9, 1990, now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4731368 |
Hoffman, Jr. et al. |
Mar 1988 |
|
4746745 |
Maren |
May 1988 |
|
4797413 |
Baldwin et al. |
Jan 1989 |
|
4847289 |
Baldwin et al. |
Jul 1989 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
1096916 |
Jan 1961 |
DEX |
1516024 |
Jun 1978 |
GBX |
Non-Patent Literature Citations (3)
Entry |
"The Reactions of Some Thiophene Sulfonyl Derivatives," Cremyln et al., Phosphorus and Sulfur, vol. 10, pp. 111-119, 1981. |
"Studien in der Thiophenreihe. XXIV..sup.2 Uber Nitrothiophene and Thiophensulfochloride," Steinkopf et al., Justus Liebigs Analen Der Chemie, vol. 501, pp. 174-186, 1933. |
"Heterocyclic Disulphonamides and Their Diuretic Properties," deStevens et al., Journal of Medicinal and Pharmaceutical Chemistry, vol. 1(6), pp. 565-576, 1959. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
618765 |
Nov 1990 |
|
Parent |
506780 |
Apr 1990 |
|